{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:18:03Z","timestamp":1783937883239,"version":"3.55.0"},"reference-count":32,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"China University Industry\u2013University\u2013Research Innovation Fund","award":["2024hr019"],"award-info":[{"award-number":["2024hr019"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Rabies remains one of the clearest therapeutic paradoxes in infectious diseases: it is largely preventable before neuroinvasion, yet once clinical symptoms appear, mortality approaches 100%. This sharp transition reflects more than delayed diagnosis alone. Wild-type rabies virus reaches and spreads within the central nervous system under conditions of relative immune silence, while the blood\u2013brain barrier (BBB) severely restricts the entry of circulating immune effectors, including virus-neutralizing antibodies. As a result, conventional immunotherapy, although highly effective in post-exposure prophylaxis, performs poorly after symptom onset because it no longer reaches the relevant compartment. This review examines whether engineered antibodies can overcome that limitation and provide a realistic path toward brain-targeted rabies immunotherapy. We first outline why symptomatic rabies remains refractory to standard immune intervention, emphasizing the combined roles of viral immune evasion and BBB-mediated anatomical exclusion. We then review recent proof-of-concept studies showing that antibody-based rescue after central nervous system invasion is biologically plausible, particularly when antibodies are delivered directly into the central nervous system (CNS), retain Fc-dependent immune activity, or are modified to improve BBB penetration. Building on these findings, we discuss key design principles for next-generation therapeutics, including epitope breadth, resistance to viral escape, Fc tuning, and delivery modules based on peptide shuttles or receptor-mediated transcytosis platforms such as TfR1- and CD98hc-targeted systems. Finally, we highlight the major translational barriers that still separate experimental rescue from clinical therapy, including the narrow therapeutic window, model limitations, safety concerns, ethical issues, implementation constraints, and the need for standardized endpoints.<\/jats:p>","DOI":"10.3390\/pharmaceutics18070848","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:51:09Z","timestamp":1783936269000},"page":"848","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Breaking the Silent Barrier: Engineering Antibodies for Brain-Targeted Rabies Immunotherapy"],"prefix":"10.3390","volume":"18","author":[{"given":"Chen","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Trauma Surgery, Wuhan Jinyintan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Provincial Hospital for Infectious Diseases, Wuhan 430023, China"},{"name":"Animal-Related Injury Treatment Center, Wuhan Jinyintan Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Trauma Surgery, Wuhan Jinyintan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Provincial Hospital for Infectious Diseases, Wuhan 430023, China"},{"name":"Animal-Related Injury Treatment Center, Wuhan Jinyintan Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Trauma Surgery, Wuhan Jinyintan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Provincial Hospital for Infectious Diseases, Wuhan 430023, China"},{"name":"Animal-Related Injury Treatment Center, Wuhan Jinyintan Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Trauma Surgery, Wuhan Jinyintan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Provincial Hospital for Infectious Diseases, Wuhan 430023, China"},{"name":"Animal-Related Injury Treatment Center, Wuhan Jinyintan Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaihong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Trauma Surgery, Wuhan Jinyintan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Provincial Hospital for Infectious Diseases, Wuhan 430023, China"},{"name":"Animal-Related Injury Treatment Center, Wuhan Jinyintan Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Trauma Surgery, Wuhan Jinyintan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Provincial Hospital for Infectious Diseases, Wuhan 430023, China"},{"name":"Animal-Related Injury Treatment Center, Wuhan Jinyintan Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Trauma Surgery, Emergency Surgery & Surgical Critical Care, Tongji Trauma Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Trauma Surgery, Emergency Surgery & Surgical Critical Care, Tongji Trauma Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1016\/S1473-3099(22)00641-7","article-title":"Human rabies despite post-exposure prophylaxis: A systematic review of fatal breakthrough infections after zoonotic exposures","volume":"23","author":"Whitehouse","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lacy, M., Phasuk, N., and Scholand, S.J. (2024). Human Rabies Treatment-From Palliation to Promise. Viruses, 16.","DOI":"10.3390\/v16010160"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1474-4422(13)70038-3","article-title":"Human rabies: Neuropathogenesis, diagnosis, and management","volume":"12","author":"Hemachudha","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/13550280802235924","article-title":"Immune evasion by rabies viruses through the maintenance of blood-brain barrier integrity","volume":"14","author":"Roy","year":"2008","journal-title":"J. Neurovirol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s13238-013-3918-8","article-title":"Role of the blood-brain barrier in rabies virus infection and protection","volume":"4","author":"Wang","year":"2013","journal-title":"Protein Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e2516465122","DOI":"10.1073\/pnas.2516465122","article-title":"A SynB1-conjugated antibody cocktail crosses the blood-brain barrier to produce a therapeutic effect on rabies","volume":"122","author":"Ren","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Pardridge, W.M. (2023). Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier. Front. Drug Deliv., 3.","DOI":"10.3389\/fddev.2023.1227816"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1038\/s41467-023-40681-4","article-title":"CD98hc is a target for brain delivery of biotherapeutics","volume":"14","author":"Chew","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Haqqani, A.S., Belanger, K., and Stanimirovic, D.B. (2024). Receptor-mediated transcytosis for brain delivery of therapeutics: Receptor classes and criteria. Front. Drug Deliv., 4.","DOI":"10.3389\/fddev.2024.1360302"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrmicro2260","article-title":"The cell biology of rabies virus: Using stealth to reach the brain","volume":"8","author":"Schnell","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kiflu, A.B. (2024). The Immune Escape Strategy of Rabies Virus and Its Pathogenicity Mechanisms. Viruses, 16.","DOI":"10.3390\/v16111774"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"12554","DOI":"10.1128\/JVI.79.19.12554-12565.2005","article-title":"Attenuated rabies virus activates, while pathogenic rabies virus evades, the host innate immune responses in the central nervous system","volume":"79","author":"Wang","year":"2005","journal-title":"J. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1128\/JVI.01964-06","article-title":"Failure to open the blood-brain barrier and deliver immune effectors to central nervous system tissues leads to the lethal outcome of silver-haired bat rabies virus infection","volume":"81","author":"Roy","year":"2007","journal-title":"J. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.1128\/JVI.00710-07","article-title":"Lethal silver-haired bat rabies virus infection can be prevented by opening the blood-brain barrier","volume":"81","author":"Roy","year":"2007","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1128\/JVI.03149-13","article-title":"Enhancement of blood-brain barrier permeability and reduction of tight junction protein expression are modulated by chemokines\/cytokines induced by rabies virus infection","volume":"88","author":"Chai","year":"2014","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1128\/JVI.02154-14","article-title":"Expression of neuronal CXCL10 induced by rabies virus infection initiates infiltration of inflammatory cells, production of chemokines and cytokines, and enhancement of blood-brain barrier permeability","volume":"89","author":"Chai","year":"2015","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2014.07.013","article-title":"Enhancement of blood-brain barrier permeability is required for intravenously administered virus neutralizing antibodies to clear an established rabies virus infection from the brain and prevent the development of rabies in mice","volume":"110","author":"Huang","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_18","first-page":"e12628","article-title":"A combination of two human monoclonal antibodies cures symptomatic rabies","volume":"12","author":"Sonthonnax","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e16394","DOI":"10.15252\/emmm.202216394","article-title":"mAb therapy controls CNS-resident lyssavirus infection via a CD4 T cell-dependent mechanism","volume":"15","author":"Mastraccio","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrmicro.2018.11","article-title":"The spread and evolution of rabies virus: Conquering new frontiers","volume":"16","author":"Fisher","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zorzan, M., Castellan, M., Gasparotto, M., Dias de Melo, G., Zecchin, B., Leopardi, S., Chen, A., Rosato, A., Angelini, A., and Bourhy, H. (2023). Antiviral mechanisms of two broad-spectrum monoclonal antibodies for rabies prophylaxis and therapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1186063"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41467-020-14398-7","article-title":"Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein","volume":"11","author":"Hellert","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"eabp9151","DOI":"10.1126\/sciadv.abp9151","article-title":"Structure of the rabies virus glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"8","author":"Callaway","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuron.2015.11.024","article-title":"Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies","volume":"89","author":"Zuchero","year":"2016","journal-title":"Neuron"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood-brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"308","DOI":"10.7150\/thno.17155","article-title":"Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor","volume":"7","author":"Hultqvist","year":"2017","journal-title":"Theranostics"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Sanchez-Navarro, M., and Giralt, E. (2022). Peptide Shuttles for Blood-Brain Barrier Drug Delivery. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14091874"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Chen, Q., Liu, Q., Gong, C., Yin, W., Mu, D., Li, Y., Ding, S., Liu, Y., Yang, H., and Zhou, S. (2023). Strategies to inTerrupt RAbies Transmission for the Elimination Goal by 2030 In China (STRATEGIC): A modelling study. BMC Med., 21.","DOI":"10.1186\/s12916-023-02821-x"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"World Medical Association (2025). Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants. J. Am. Med. Assoc., 333, 71\u201374.","DOI":"10.1001\/jama.2024.21972"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s13063-022-06304-x","article-title":"Trials using deferred consent in the emergency setting: A systematic review and narrative synthesis of stakeholders\u2019 attitudes","volume":"23","author":"Fitzpatrick","year":"2022","journal-title":"Trials"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"A85","DOI":"10.1016\/j.vaccine.2018.10.014","article-title":"The WHO position on rabies immunization\u20142018 updates","volume":"37","author":"Nolan","year":"2019","journal-title":"Vaccine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1016\/j.vaccine.2019.04.024","article-title":"Overview of rabies post-exposure prophylaxis access, procurement and distribution in selected countries in Asia and Africa, 2017\u20132018","volume":"37","author":"Sreenivasan","year":"2019","journal-title":"Vaccine"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/7\/848\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:54:14Z","timestamp":1783936454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/7\/848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["pharmaceutics18070848"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18070848","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,12]]}}}